Tumors of several sites in human and experimental animals can be effectively prevented by inhibitors of arachidonic acid metabolism. Inhibitors of lipoxygenases (LOX) in particular have strong chemopreventive activity in the murine multistage skin carcinogenesis model. In this model some of the LOX products are known to be required for the inflammatory and angiogenic response to tumor promoters and for tumor growth. Unlike other members of the LOX """"""""family,"""""""" 8-LOX is highly inducible in promotion-sensitive mice but not in promotion-resistant mice. It is also constitutively overexpressed in skin tumors. The function of the products of 8-LOX, primarily 8-hydroxyeicosatetraenoic acid (8-HETE), are unknown; however, preliminary data indicate that 8-HETE is an activator of peroxisome proliferator activated receptors (PPARs) in keratinocytes and that PPARs mediate 8-HETE induction of keratin- 1. The applicant has generated an 8- LOX transgenic mouse with the transgene targeted to the epidermis. These mice show a greatly increased propensity for progression from papillomas to carcinomas. Based on these observations, she hypothesizes that one or more of the products of 8-LOX are required for, or contribute to, susceptibility to skin tumor development and that this occurs via a peroxisome proliferator activated receptor (PPAR) mechanism. She also proposes that elevated 8-LOX contributes to tumor development by causing a regenerative response in the epidermis that results in increased stem cell turnover. The specific questions to be addressed are: (1) Does 8-LOX confer increased susceptibility to skin tumor development? (2) How do the products of 8- LOX increase susceptibility? (3) What is the mechanistic basis for the constitutive upregulation of 8-LOX expression in tumors? (4) Do 8-HETE or 9-HODE exert their effects by binding to and activating one or more of the PPAR isoforms in keratinocytes? Is the PPAR alpha isoform required for 8-HETE effects on differentiation and skin tumor susceptibility?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA083794-04
Application #
6607721
Study Section
Chemical Pathology Study Section (CPA)
Program Officer
Yang, Shen K
Project Start
2000-07-01
Project End
2005-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
4
Fiscal Year
2003
Total Cost
$349,568
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Organized Research Units
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Kim, Eunjung; Rundhaug, Joyce E; Benavides, Fernando et al. (2005) An antitumorigenic role for murine 8S-lipoxygenase in skin carcinogenesis. Oncogene 24:1174-87
He, Guobin; Thuillier, Philippe; Fischer, Susan M (2004) Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARgamma in normal mouse skin keratinocytes. J Invest Dermatol 123:1110-9
Kim, Eunjung; Muga, Stephanie J; Fischer, Susan M (2004) Identification and characterization of a phorbol ester-responsive element in the murine 8S-lipoxygenase gene. J Biol Chem 279:11188-97
Thuillier, Philippe; Brash, Alan R; Kehrer, James P et al. (2002) Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors. Biochem J 366:901-10
Muga, S J; Thuillier, P; Pavone, A et al. (2000) 8S-lipoxygenase products activate peroxisome proliferator-activated receptor alpha and induce differentiation in murine keratinocytes. Cell Growth Differ 11:447-54